Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: Clinical and genotypic predictors of virologic response
Autore:
Shulman, NS; Zolopa, AR; Passaro, DJ; Murlidharan, U; Israelski, DM; Brosgart, CL; Miller, MD; Van Doren, S; Shafer, RW; Katzenstein, DA;
Indirizzi:
Stanford Univ, Sch Med, Div Infect Dis, Stanford, CA 94305 USA Stanford Univ Stanford CA USA 94305 iv Infect Dis, Stanford, CA 94305 USA Gilead Sci Inc, Foster City, CA USA Gilead Sci Inc Foster City CA USAGilead Sci Inc, Foster City, CA USA
Titolo Testata:
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
fascicolo: 3, volume: 23, anno: 2000,
pagine: 221 - 226
SICI:
1525-4135(20000301)23:3<221:EAADST>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE-TRANSCRIPTASE; NONNUCLEOSIDE INHIBITORS; IN-VITRO; RESISTANCE; LAMIVUDINE; SUSCEPTIBILITIES; COMBINATIONS; DIDANOSINE; NEVIRAPINE;
Keywords:
efavirenz; adefovir; genotype; salvage therapy; virologic response;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
19
Recensione:
Indirizzi per estratti:
Indirizzo: Shulman, NS Stanford Univ, Sch Med, Div Infect Dis, 300 Pasteur Dr,Room S-156, Stanford, CA 94305 USA Stanford Univ 300 Pasteur Dr,Room S-156 Stanford CA USA 94305
Citazione:
N.S. Shulman et al., "Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: Clinical and genotypic predictors of virologic response", J ACQ IMM D, 23(3), 2000, pp. 221-226

Abstract

Objective: To determine the impact of prior nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy, genotypic resistance, and other variables on response to efavirenz (EFV)- and adefovir dipivoxil (ADV)-based salvage therapy. Design: Retrospective clinical cohort study. Setting: One university and one community-based HIV clinic. Study subjects: All 33 patients who were coenrolled in both the EFV and ADV expanded access programs,Interventions: Patients received EFV 600 mg/day and ADV 120 mg/day in,addition to other antiretroviral agents. Outcome measure: HIV viral load (<500 copies/ml) at 12 and 24 weeks. Results: 10 of 33 (30%) patients at 12 weeks and 8 of 33 (24%) patients at24 weeks had viral loads <500 copies/ml. Prior NNRTI use and a history of any NNRTI-associated mutations predicted failure. Patients with Y181C or G190A single mutations had an initial greater magnitude of viral load suppression than those with K103N, but this advantage was short lived. No one withany NNRTI mutations responded with a viral load <500 copies/ml at 12 or 24weeks. Conclusions: EFV/ADV-based salvage yielded viral load suppression at 24 weeks in 42% (8 of 19) of patients who were highly NRTI and protease inhibitor experienced but NNRTI naive. NNRTI-experienced study subjects had a poor response regardless of the specific NNRTI resistance mutation they harbored.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/04/20 alle ore 21:39:56